Petros Pharmaceuticals Inc. has released its unaudited pro forma consolidated balance sheets, shedding light on the financial implications of its recent M&A activities. The statements, dated March 31, 2025, reflect adjustments related to the deconsolidation of subsidiaries and a settlement with Vivus. Notably, the company's common stock saw an increase in issued and outstanding shares to 2,052,762, up from 421,124, as a result of these transactions. Additional paid-in capital rose significantly, reaching approximately $115.99 million, while accumulated deficits were adjusted to $107.99 million. The adjustments also reflect changes in liabilities, with the accounts payable and accrued expenses being notably reduced. These financial statements provide a clearer picture of Petros Pharmaceuticals' financial position following the recent strategic transactions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.